Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report 2024: Rapid Expansion Fueled by API Complexity and Cost Reduction Needs – Global Forecast to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product, By Synthesis, By Drug, By Application, By Workflow, By Region, And Segment Forecasts, 2024 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The global active pharmaceutical ingredient CDMO market size was valued at USD 164.5 billion in 2030 and is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2030

Increasing pharmaceutical R&D investments, patent expirations, and a rise in demand for generic drugs and biologic innovations propelling outsourcing are the factors driving the market.

The growth of small molecules, rising active pharmaceutical ingredient (API) complexity and the need to reduce costs are factors contributing to the rapid expansion of outsourcing services in the pharmaceutical sector. Only a few companies have achieved global reach and scale in the contract development and manufacturing organization (CDMO) sector, which is still fragmented. Besides, many companies are providing one-stop-shop solutions as an integrated source of APIs and formulations.

As the healthcare industry is undergoing a process of dynamic change, factors such as rapid technological advancements (e.g., automation & AI), the need for CROs/CMOs/CDMOs, and rising investments in research are influencing the healthcare market. The outsourcing of activities is benefitting many pharmaceutical companies in improving their operational efficiencies, expanding their geographical presence, decreasing resource costs, gaining therapeutic expertise, and enhancing on-demand services.

The COVID-19 pandemic placed unprecedented expectations on API makers, as evidenced by the substantial increase in demand for medications required to manage critically ill patients on mechanical ventilation. As a result, the sudden need to rapidly increase production has emphasized the need for adaptability for API CDMOs in maintaining drug supply, with some companies proving to be better prepared to withstand the pressures of quick scale-up than others. Growing demand for new therapies worldwide and an increase in the conduction of clinical research in the post-pandemic period are expected to support the market in the coming years.

Active Pharmaceutical Ingredient CDMO Market Report Highlights

• The traditional active pharmaceutical ingredient segment dominated the market and accounted for the largest revenue share of 39.8% in 2022, due to the high adoption of traditional API in majority of pharmaceuticals
• The innovative drugs segment held 73.7% of the revenue share in 2022. This is largely attributed to increasing FDA approvals for new molecular entities, and the increased focus on R&D by innovator API companies
• The oncology segment led the market with the highest revenue share of 35.5% in 2022. This is due to the increasing demand for highly potent APIs for cancer therapy
• The biotech segment is expected to grow at the fastest rate of 7.0% over the forecast period, owing to the high adoption of biopharmaceuticals in the treatment of chronic and infectious diseases
• The clinical workflow segment is anticipated to witness the fastest CAGR of 7.3% over the forecast period. An increase in the number of clinical research studies supporting the demand for APIs is one of the key factors driving segment growth
• In Asia Pacific, the market is expected to register the fastest CAGR of 9.1% over the forecast period. Due to the extreme growth in the number of pharmaceutical companies and contract manufacturing organizations in developing countries such as India and China, the region is likely to overtake Europe and North America in the near future

Company Profiles

• Cambrex Corporation
• Recipharm CP
• Thermo Fisher Scientific Inc. (Pantheon)
• CordenPharma International
• Samsung Biologics
• Lonza
• Catalent, Inc.
• Siegfried Holding AG
• Piramal Pharma Solutions
• Boehringer Ingelheim International GmbH

Key Attributes:

Report Attribute	Details
No. of Pages	137
Forecast Period	2023 – 2030
Estimated Market Value (USD) in 2023	$100.4 Billion
Forecasted Market Value (USD) by 2030	$164.5 Billion
Compound Annual Growth Rate	7.4%
Regions Covered	Global

Key Topics Covered:

Chapter 1. Active Pharmaceutical Ingredient CDMO Market: Methodology and Scope

1.1. Market Segmentation And Scope

1.2. Regional Scope

1.3. Estimates And Forecast Timeline

1.4. Objectives

1.5. Research Methodology

1.6. Information Procurement

1.7. Information or Data Analysis

1.8. Market Formulation & Validation

1.9. Model Details

1.10. List of Primary Sources

1.11. List of Abbreviations

Chapter 2. Active Pharmaceutical Ingredient CDMO Market: Executive Summary

2.1. Market Snapshot

2.2. Products And Synthesis Snapshots

2.3. Drug And Application Snapshot

2.4. Workflow Snapshot

2.5. Competitive Landscape Snapshot

Chapter 3. Active Pharmaceutical Ingredient CDMO Market: Variables, Trends, & Scope

3.1. Market Segmentation And Scope

3.2. Market Lineage Outlook

3.2.1. Parent Market Outlook

3.2.2. Related/Ancillary Market Outlook

3.3. Market Dynamics

3.4. Market Drivers Analysis

3.4.1. Increase in pharmaceutical R&D investment

3.4.2. Rapid demand for generic drugs

3.4.3. Patient expiration

3.4.4. Expanding consumption of biopharmaceuticals

3.5. Market Restraint Analysis

3.5.1. Compliance issues while outsourcing

3.6. Active Pharmaceutical Ingredient CDMO Market Analysis Tools

3.6.1. Industry Analysis – Porter’s Five Forces

3.6.2. PESTLE Analysis

Chapter 4. Active Pharmaceutical Ingredient CDMO Market: Product Estimates & Trend Analysis

4.1. Product Market Share, 2023 & 2030

4.2. Segment Dashboard

4.3. Global Active Pharmaceutical Ingredient CDMO Market, Product Outlook

4.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:

4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API)

4.4.2. Highly Potent Active Pharmaceutical Ingredient (HP-API)

4.4.3. Antibody Drug Conjugate (ADC)

4.4.4. Others

Chapter 5. Active Pharmaceutical Ingredient CDMO Market: Synthesis Estimates & Trend Analysis

5.1. Synthesis Market Share, 2023 & 2030

5.2. Segment Dashboard

5.3. Global Active Pharmaceutical Ingredient CDMO Market, Synthesis Outlook

5.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:

5.4.1. Synthetic

5.4.2. Biotech

Chapter 6. Active Pharmaceutical Ingredient CDMO Market: Drug Estimates & Trend Analysis

6.1. Drug Market Share, 2023 & 2030

6.2. Segment Dashboard

6.3. Global Active Pharmaceutical Ingredient CDMO Market, Drug Outlook

6.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:

6.4.1. Innovative

6.4.2. Generics

Chapter 7. Active Pharmaceutical Ingredient CDMO Market: Application Estimates & Trend Analysis

7.1. Application Market Share, 2023 & 2030

7.2. Segment Dashboard

7.3. Global Active Pharmaceutical Ingredient CDMO Market, Application Outlook

7.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:

7.4.1. Oncology

7.4.2. Hormonal

7.4.3. Glaucoma

7.4.4. Cardiovascular Disease

7.4.5. Diabetes

7.4.6. Others

Chapter 8. Active Pharmaceutical Ingredient CDMO Market: Workflow Estimates & Trend Analysis

8.1. Workflow Market Share, 2023 & 2030

8.2. Segment Dashboard

8.3. Global Active Pharmaceutical Ingredient CDMO Market, Workflow Outlook

8.4. Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Following:

8.4.1. Clinical

8.4.2. Commercial

Chapter 9. Active Pharmaceutical Ingredient CDMO Market: Regional Business Analysis

9.1. Regional Market Share Analysis, 2023 & 2030

9.2. Regional Market Dashboard

9.3. Global Regional Market Snapshot

9.4. Marker Size, & Forecasts Trend Analysis, 2018 To 2030

Chapter 10. Competitive Landscape

10.1. Recent Developments & Impact Analysis, By Key Market Participants

10.2. Company /Competition Categorization

10.3. Vendor Landscape

10.3.1. List Of Key Distributors And Channel Partners

10.3.2. Key Customers

10.3.3. Key Company Market Share Analysis, 2023

For more information about this report visit https://www.researchandmarkets.com/r/kdzxi2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900